Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that
affects patients' function, quality of life, and ability to tolerate treatment. In certain patients …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Background A variety of dermatoses have been reported in the growing number of patients
treated with immune-checkpoint inhibitors (ICIs), but the current understanding of cutaneous …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of
tumor-mediated immune evasion. The frequency of its use has increased rapidly and has …

Antineoplastic agents that use the immune system have revolutionized cancer treatment.
Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …

The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented
treatment benefits being obtained for cancer patients, including improved patient survival …